Introduction

Research Problem and Rationale

The need for a better understanding of tumor dynamics is critical to improving cancer treatment outcomes. Tumor growth is a multifaceted process influenced by genetic mutations, cell proliferation rates, interactions with the immune system, and the surrounding microenvironment. Traditional experimental approaches often fall short of capturing the full scope of these complexities. Mathematical modeling offers a powerful alternative by allowing researchers to analyze how tumors evolve over time, considering factors like angiogenesis, nutrient availability, and immune evasion.

One of the most significant contributions of mathematical models in cancer research is their ability to simulate tumor growth under various treatment scenarios. By incorporating factors such as drug pharmacokinetics, radiation dosage, or immune responses, these models can predict how different treatments will affect tumor size and composition (Vieira et al., 2023). This capability is particularly valuable in personalizing treatment plans for individual patients, as it enables oncologists to predict which therapies might be most effective based on a patient’s unique tumor biology.

Figure 1. Schematic representation of tumor microenvironment and its dynamic interactions.

Figure 1. Schematic representation of tumor microenvironment and its dynamic interactions.

The rationale for using mathematical models is clear: they provide a framework for systematically investigating tumor dynamics, offering predictive power that experimental methods alone cannot achieve (Azizi, 2024). This approach not only enhances our understanding of how tumors grow and spread but also helps in optimizing therapeutic strategies, potentially improving patient survival rates and reducing side effects from overtreatment.

Overview of Cancer Biology and Tumor Growth

Basic Cancer Biology

Cancer is a broad term for a group of diseases characterized by the uncontrolled growth and spread of abnormal cells. Unlike normal cells, which follow a regulated cell cycle, cancer cells divide uncontrollably, forming tumors that can invade nearby tissues and metastasize to distant organs. Tumors can be classified as either benign or malignant (National Cancer Institute, 2021). Benign tumors are non-cancerous and usually do not spread, whereas malignant tumors are cancerous and possess the potential to invade other parts of the body.

Figure 2. Cancer cell and normal cell.

Figure 2. Cancer cell and normal cell.

Cancer progresses through several stages, typically defined by the size of the tumor and its spread. In early-stage cancer, the tumor is confined to its original site. As the disease advances, the cancerous cells invade surrounding tissues and, in later stages, may metastasize through the bloodstream or lymphatic system to distant organs. The molecular mechanisms driving tumor growth are rooted in genetic mutations and dysregulation of the cell cycle. Normal cell division is tightly controlled by checkpoints in the cell cycle, where DNA is repaired before the cell divides (National Cancer Institute, 2021). However, in cancer cells, mutations in oncogenes, tumor suppressor genes, and DNA repair genes lead to unchecked proliferation. These genetic alterations can occur due to exposure to carcinogens, such as tobacco smoke or UV radiation, or arise from inherited genetic mutations.

The cell cycle is central to tumor growth, with several key proteins involved in regulating cell division. Mutations in genes like TP53, which encodes a tumor suppressor protein, and genes controlling growth factors like epidermal growth factor receptor (EGFR) contribute to the development and progression of cancer (National Cancer Institute, 2021). As these cells divide uncontrollably, tumors grow and evolve, acquiring further mutations that enhance their survival, proliferation, and ability to evade the immune system.

Tumor Microenvironment

The tumor microenvironment (TME) is composed of the non-cancerous cells, molecules, and blood vessels that surround and interact with the tumor. Far from being passive bystanders, these components play an active role in tumor progression (de Visser & Joyce, 2023). Tumor cells communicate with the surrounding stroma, which includes fibroblasts, immune cells, and the extracellular matrix, to create a supportive niche that promotes growth and invasion.

One critical aspect of the TME is its interaction with the immune system. While the immune system is capable of identifying and eliminating abnormal cells, cancer cells can evade immune detection by expressing proteins that suppress immune responses (de Visser & Joyce, 2023). For example, they can inhibit cytotoxic T-cells, which are responsible for attacking cancer cells, or upregulate immune checkpoint proteins like PD-L1 that act as a shield against immune attack. This immune evasion allows the tumor to grow unchecked.

Figure 3. The tumor microenvironment (TME) representation.

Figure 3. The tumor microenvironment (TME) representation.

Another key process in the TME is angiogenesis, the formation of new blood vessels that supply the tumor with oxygen and nutrients. As tumors grow, they can outstrip their blood supply, leading to hypoxia (low oxygen levels). In response, cancer cells secrete factors like vascular endothelial growth factor (VEGF), which stimulates the growth of new blood vessels to nourish the expanding tumor (de Visser & Joyce, 2023). This process not only supports tumor growth but also provides a route for cancer cells to enter the bloodstream and metastasize to distant organs.

Introduction to Biomathematics in Cancer Research

Key Mathematical Concepts in Tumor Modeling

Tumor modeling relies on several key mathematical concepts, each offering unique insights into cancer biology. One of the most fundamental tools in biomathematics is the use of differential equations to describe the changes in tumor size over time (Yin et al., 2019). Differential equations allow researchers to model continuous processes such as cell proliferation, nutrient consumption, and the effect of treatments like chemotherapy or radiation. For example, the Gompertz equation is often used to model tumor growth, providing a realistic description of how tumors grow rapidly at first but slow down as they encounter limitations in resources like oxygen and nutrients.

Figure 4. mathematical oncology.

Figure 4. mathematical oncology.

Another important concept in tumor modeling is stochastic models, which account for the inherent randomness and variability in biological systems. While differential equations provide a deterministic framework, assuming that given initial conditions always produce the same outcome, stochastic models incorporate the unpredictable nature of processes like gene mutations or the immune system's response to cancer (Yin et al., 2019). These models are particularly useful for understanding rare events, such as the emergence of drug-resistant cancer cells or the probability of metastasis.

Figure 5. Cellular automation.

Figure 5. Cellular automation.

The role of computational tools in mathematical cancer models cannot be overstated. As the complexity of these models has increased, so has the need for sophisticated software and algorithms to solve them. Computational tools allow researchers to run simulations that would be impossible to calculate by hand, often involving millions of variables and interactions (Matin & Setayeshi, 2024). Software platforms like MATLAB, R, and Python’s scientific libraries are commonly used to implement and analyze cancer models. These tools provide the computational power necessary to explore different treatment scenarios, optimize drug dosages, and predict patient outcomes.

Mathematical Models for Tumor Growth

Deterministic Models

Deterministic models describe tumor growth through mathematical equations that predict the evolution of the tumor size over time. These models are "deterministic" because, given the same initial conditions, they always produce the same outcome without incorporating random variations (Alinei-Poiana et al., 2023). Three of the most commonly used deterministic models are the exponential, logistic, and Gompertz models.

Exponential Growth Model: The simplest model for tumor growth is the exponential model, which assumes that cancer cells divide at a constant rate, leading to a continuous and rapid increase in tumor size (Johnson et al., 2019). Mathematically, the model is expressed as:

where N(t) is the number of cells at time t₁, N₀ is the initial number of cells, and r is the growth rate. This model is useful for describing early tumor growth, where resources such as nutrients and space are abundant. However, the exponential model becomes unrealistic as the tumor size increases, as it does not account for the biological limitations that slow growth in larger tumors.

Logistic Growth Model: To account for these limitations, the logistic model introduces a carrying capacity K, which represents the maximum tumor size that the environment can support. The logistic model is expressed as:

This model shows rapid growth at the beginning, followed by a deceleration as the tumor size approaches K. The logistic model is particularly useful for simulating the behavior of tumors as they face constraints like limited nutrients and immune system pressure (Harshe et al., 2023).

Gompertz Model: The Gompertz model is another refinement that captures the slowing of tumor growth more accurately, especially in later stages. It is expressed as:

where r and b are constants. The Gompertz model assumes that the growth rate decreases exponentially as the tumor grows, which aligns with empirical data for many solid tumors. It is commonly used in oncology to describe the long-term growth of tumors and to predict treatment responses, especially in the context of chemotherapy.

Applications: Deterministic models are widely used in the early stages of tumor development. For instance, the exponential model is often applied in studies where researchers examine the initial rapid proliferation of cancer cells (Johnson et al., 2019). The logistic and Gompertz models, meanwhile, provide more realistic simulations of tumor growth over extended periods, helping to understand how tumors respond to changes in their environment, such as nutrient depletion or immune responses. These models are foundational in cancer research, forming the basis for more complex approaches.

Stochastic Models

While deterministic models provide clear predictions, biological systems like tumors are inherently random. Stochastic models incorporate elements of randomness to capture this uncertainty, making them more realistic for modeling cancer progression (Odoux et al., 2019).

Figure 6. Models of tumor development - Stochastic Models.

Figure 6. Models of tumor development - Stochastic Models.

How Randomness is Used: Stochastic models account for random variations in processes like cell division, mutation, and death. For example, in a population of tumor cells, not every cell will divide at the same rate, and some may acquire mutations that affect their growth. The probability of a cell dividing, dying, or mutating is represented by a stochastic process, such as a Poisson or Markov process.

A common stochastic model is the birth-death process, which describes the probability of a cell population growing or shrinking over time. (Lunk, 2019) The transition rates between states (e.g., the probability of a cell dividing or dying) depend on factors like the availability of nutrients or the effects of treatment. Stochastic models are especially useful in capturing rare events, such as the emergence of drug-resistant cancer cells, which may occur infrequently but have a significant impact on treatment outcomes.

Figure 1. stochastic dynamics of population growth

Figure 1. stochastic dynamics of population growth

Incorporation of Random Mutations and Cell Death: Stochastic models are essential for modeling genetic mutations, which occur randomly and can drive cancer progression. By incorporating mutation probabilities, these models can simulate the development of cancer subclones that may be more aggressive or resistant to therapy (Foo et al., 2011). This is crucial for understanding how heterogeneity arises within a tumor and how this heterogeneity influences treatment resistance and metastasis.

Applications: Stochastic models are widely used in cancer research to simulate the random processes that influence tumor evolution. For instance, they can model the impact of random genetic mutations on the development of drug resistance, helping researchers design better treatment strategies. Additionally, stochastic models are often used in the study of cancer metastasis, where the random detachment and spread of cancer cells to distant organs are critical processes (Castaneda et al., 2022).

Multiscale Models

Multiscale models bridge different biological scales, from the genetic and molecular level to the tissue and organ level, to provide a more comprehensive picture of tumor growth. Cancer is a multiscale disease, where changes at the genetic or molecular level can have profound effects on cellular behavior, tissue architecture, and organ function (Deisboeck et al., 2011). Multiscale models aim to capture this complexity by integrating information across these different levels.

Figure 8. Schematic illustration of the biological scales of significant relevance for cancer modeling.

Figure 8. Schematic illustration of the biological scales of significant relevance for cancer modeling.

Combining Biological Scales: A typical multiscale model might combine a genetic model that describes mutations in cancer cells with a cellular model that simulates how those mutations affect cell behavior (e.g., proliferation or apoptosis) (Nivlouei et al, 2022). This, in turn, is linked to a tissue-scale model that describes how the tumor interacts with its surrounding environment, including blood vessels, immune cells, and extracellular matrix.

Figure 9. An illustration of the spatiotemporal multiscale modeling framework.

Figure 9. An illustration of the spatiotemporal multiscale modeling framework.

Predicting Metastasis: One of the key applications of multiscale models is in predicting metastasis, the process by which cancer cells spread from the primary tumor to other parts of the body. Metastasis involves multiple steps, including the detachment of cancer cells from the primary tumor, invasion into surrounding tissues, entry into the bloodstream or lymphatic system, and colonization of distant organs (Petinrin et al., 2023). Multiscale models can simulate these processes, providing insights into which factors drive metastasis and how it might be prevented.

Figure 10. Engineered models to parse apart the metastatic.

Figure 10. Engineered models to parse apart the metastatic.

Applications: Multiscale models are highly valuable in understanding the complex interactions that occur within a tumor and between a tumor and its environment. They have been used to study how genetic mutations drive tumor growth, how cancer cells evade the immune system, and how treatments like radiation therapy affect both cancer cells and surrounding normal tissues (Norton et al., 2019). These models are increasingly being used to guide the development of personalized cancer therapies by simulating how a patient’s tumor might respond to different treatment options.

Agent-Based Models

Agent-based models (ABMs) take a different approach to tumor modeling by treating individual cells as "agents" that follow specific rules (Poleszczuk et al., 2016). Each cell is modeled as an independent entity with its own set of behaviors, such as proliferation, migration, or death, which depend on the cell’s internal state and its interactions with other cells and the environment.

Figure 11. gent-based modeling in cancer biomedicine.

Figure 11. gent-based modeling in cancer biomedicine.

Modeling Individual Cells as Agents: In an ABM, the behavior of each cell is governed by rules that describe how it interacts with its neighbors and the surrounding environment. For example, a cancer cell might proliferate if it has enough nutrients and space, but it might die if it encounters immune cells or is starved of oxygen (West et al., 2023). The overall tumor behavior emerges from the collective actions of thousands or millions of individual cells, each following its own rules.

Benefits of Agent-Based Models: One of the key advantages of ABMs is their ability to capture the heterogeneity of tumor cells. Tumors are not homogeneous masses of identical cells; instead, they consist of a diverse population of cells with different genetic mutations, behaviors, and responses to treatment (Belkhir et al., 2021). ABMs can simulate this heterogeneity, providing insights into how different subpopulations of cancer cells interact with each other and how this affects tumor growth and treatment response.

Applications: ABMs are particularly useful for studying tumor heterogeneity and the spatial organization of tumors. For instance, they have been used to simulate how different cancer cell subpopulations compete for resources within a tumor, how cancer cells invade surrounding tissues, and how treatments like immunotherapy affect individual cancer cells (Belkhir et al., 2021). ABMs are also valuable for studying the interactions between cancer cells and other cell types in the tumor microenvironment, such as immune cells and fibroblasts.

Hybrid Models

Hybrid models combine different mathematical approaches to capture the complexity of tumor growth. For example, a hybrid model might combine a deterministic model that describes the overall growth of the tumor with a stochastic model that captures random mutations and an agent-based model that simulates the behavior of individual cancer cells (Gonçalves & GarcíaAznar, 2023).

Figure 12. Schematic representation of hybrid models.

Figure 12. Schematic representation of hybrid models.

Combining Mathematical Approaches: By combining different types of models, hybrid models can provide a more comprehensive view of tumor growth. For instance, a hybrid model might use a deterministic model to describe the overall growth of the tumor while incorporating stochastic elements to account for the randomness of genetic mutations and an agent-based component to simulate the behavior of individual cancer cells (Chamseddine & Rejniak, 2019).

Case Studies: Hybrid models have been used in several case studies to simulate tumor growth and treatment response. One notable example is the use of hybrid models to study the evolution of drug resistance in cancer (Szumilak et al., 2021). By combining deterministic models of tumor growth with stochastic models of mutation and agent-based models of cell behavior, researchers have been able to simulate how cancer cells evolve resistance to chemotherapy and suggest strategies for overcoming this resistance. Hybrid models have also been used to study metastasis, combining multiscale models of tissue invasion with stochastic models of cell migration.

Applications: Hybrid models are becoming increasingly popular in cancer research due to their ability to capture the complexity of tumor growth and treatment response. They are particularly useful for studying the evolution of cancer over time, including the development of drug resistance, the spread of metastasis, and the effects of combination therapies (Chamseddine & Rejniak, 2019). Hybrid models are also being used in personalized medicine, where they can simulate how an individual patient’s tumor might respond to different treatments based on its unique characteristics.

Figure 13. Mathematical modeling in cancer treatment.

Figure 13. Mathematical modeling in cancer treatment.

Mathematical Models for Cancer Treatment Optimization

Chemotherapy Modeling

Chemotherapy remains a cornerstone in cancer treatment, but its efficacy is often limited by factors such as drug resistance, toxicity, and tumor regrowth. Mathematical models have been instrumental in addressing these challenges by helping optimize chemotherapy dosage, timing, and combinations.

Optimizing Drug Dosage and Schedules: Mathematical models are used to identify optimal dosing schedules that maximize the killing of cancer cells while minimizing harm to healthy tissue. One common approach is to use pharmacokinetic (PK) and pharmacodynamic (PD) models, which describe how the drug is absorbed, distributed, metabolized, and excreted (PK), and how it affects the tumor and healthy cells (PD) (Sun & Hu, 2018). These models use differential equations to represent the concentration of the drug in the bloodstream over time and its effect on cell populations.

For example, in a standard model, the rate of tumor cell death may depend on the concentration of the drug and the sensitivity of the tumor cells to treatment:

where N(t) is the number of tumor cells at time t₁, C(t) is the drug concentration, and k is a constant representing drug efficacy. By simulating various dosing regimens, these models can help determine whether high doses given infrequently or lower doses administered more frequently yield better results.

Modeling Drug Resistance and Tumor Regrowth: One of the major challenges in chemotherapy is the development of drug resistance, which can lead to tumor regrowth after an initial period of remission. Mathematical models of drug resistance typically involve stochastic processes that account for random mutations in cancer cells that make them resistant to chemotherapy (Yin et al., 2019). These models can simulate the emergence of resistant cell populations and help identify treatment strategies that delay or prevent resistance.

For instance, a common approach is to model the growth of both sensitive and resistant cancer cells using a set of differential equations:

where S(t) and R(t) represent the populations of sensitive and resistant cells, respectively, r_s and r_r are the growth rates, K is the carrying capacity of the tumor environment, and k_s and k_r are the effects of the drug on sensitive and resistant cells. These models provide insight into the timing and dosing strategies that might minimize the development of resistance, leading to more effective long-term treatment outcomes.

Radiation Therapy Models

Radiation therapy, another common cancer treatment, relies on high-energy radiation to kill tumor cells by damaging their DNA. The challenge is to deliver a sufficient dose to eradicate the tumor while minimizing damage to surrounding healthy tissue (Bekker et al., 2022). Mathematical models have been developed to optimize radiation therapy protocols by predicting the effects of different doses and schedules on both tumor shrinkage and normal tissue response.

Optimizing Radiation Doses: One of the most widely used models in radiation therapy is the linear-quadratic (LQ) model, which describes the relationship between radiation dose and cell survival (Li, 2023). The model is based on the idea that radiation kills cells through two mechanisms: single-hit lethal events (linear term) and double-hit events (quadratic term). The LQ model is expressed as:

where S(D) is the surviving fraction of cells after a dose D of radiation, and α and β are constants that depend on the sensitivity of the tumor and normal tissues to radiation. By fitting clinical data to the LQ model, researchers can predict how different radiation doses will affect tumor control and normal tissue toxicity, helping to tailor treatment to the individual patient.

Models Predicting Tumor Shrinkage and Normal Tissue Response: In addition to the LQ model, other mathematical frameworks, such as tumor control probability (TCP) models, are used to predict the likelihood of completely eradicating a tumor with a given radiation dose (Spoormans et al., 2022). These models are often combined with normal tissue complication probability (NTCP) models, which predict the risk of damage to healthy tissues. By balancing TCP and NTCP, radiation oncologists can design treatment plans that maximize tumor control while minimizing side effects.

Immunotherapy Modeling

Immunotherapy represents a major breakthrough in cancer treatment, harnessing the power of the immune system to recognize and destroy cancer cells. However, predicting the response to immunotherapy is complex due to the dynamic interactions between cancer cells, immune cells, and the tumor microenvironment (Butner et al., 2022). Mathematical models are playing a critical role in simulating these interactions and guiding the development of more effective immunotherapies.

Simulation of Immune-Tumor Dynamics: Mathematical models of immunotherapy often involve ordinary differential equations (ODEs) that describe the interactions between tumor cells and various components of the immune system, such as T cells, natural killer (NK) cells, and cytokines (Unni & Seshaiyer, 2019). These models simulate how the immune system recognizes and attacks tumor cells, as well as how cancer cells evade immune detection.

For example, a simple model of immune-tumor dynamics might include equations for the growth of tumor cells and the activity of immune cells:

where T(t) is the tumor cell population, I(t) is the immune cell population, r is the tumor growth rate, k is the rate at which immune cells kill tumor cells, s is the immune response rate, and d is the rate of immune cell decay. By adjusting these parameters, the model can simulate different immunotherapy strategies, such as checkpoint inhibitors or CAR-T cell therapy, and predict how the tumor will respond.

Models for Predicting the Efficacy of Immunotherapeutic Agents: Another approach involves agent-based models (ABMs), where individual immune cells and tumor cells are treated as agents with specific behaviors. These models allow for detailed simulations of how immune cells infiltrate the tumor, interact with cancer cells, and respond to immunotherapeutic agents (Norton et al., 2019). ABMs can capture the spatial heterogeneity of tumors and the complex dynamics of immune-tumor interactions, making them valuable tools for designing personalized immunotherapy treatments.

Case Studies of Mathematical Models in Cancer Research

Case Study 1: Predicting Tumor Growth with the Gompertz Model

The Gompertz model is one of the most widely used mathematical models for predicting tumor growth. It is particularly useful for describing the slowing of tumor growth as the tumor approaches a certain size, a characteristic that distinguishes it from simpler exponential growth models (Heesterman et al., 2019). The Gompertz model posits that the growth rate of a tumor decreases exponentially as the tumor size increases, reflecting the biological reality that tumors tend to grow more slowly as they expand and encounter environmental constraints, such as limited nutrients or immune suppression.

The Gompertz equation is given by:

where N(t) is the tumor size at time t₁, N₀​ is the initial tumor size, b is the initial growth rate, and c is a parameter related to the rate of growth deceleration.

Real-world Application: The Gompertz model has been applied in various clinical studies to predict tumor growth dynamics across several cancer types, including breast cancer and gliomas. For example, in a study involving breast cancer patients, the Gompertz model was used to predict the tumor's progression over time, both before and after treatment (Clare et al., 2000). The model’s predictions closely aligned with the observed tumor growth patterns, demonstrating its effectiveness in capturing the sigmoidal nature of tumor growth.

Accuracy and Limitations: While the Gompertz model accurately reflects many observed growth patterns, particularly during the later stages of tumor progression, it has limitations. One significant drawback is its assumption that tumor growth decelerates solely due to size-related constraints, which may oversimplify the complex biological interactions occurring in the tumor microenvironment (Heesterman et al., 2019). For instance, factors such as immune evasion, genetic mutations, and tumor heterogeneity are not explicitly accounted for in this model. Additionally, the Gompertz model may not perform well when tumors are in their early stages of growth, where exponential models might be more appropriate.

Despite these limitations, the Gompertz model remains a valuable tool for predicting tumor growth, particularly when combined with other models that account for early-stage dynamics or tumor-specific factors. Its ability to predict long-term growth trends makes it useful in clinical settings, particularly for monitoring tumor progression or evaluating treatment efficacy over time.

Case Study 2: Optimizing Chemotherapy Through Mathematical Models

Optimizing chemotherapy involves finding the right balance between killing cancer cells and minimizing harm to healthy tissue, a challenge that mathematical models have been instrumental in addressing. Several models have been developed to optimize drug dosing and timing, including those that simulate drug resistance and tumor regrowth.

Application of Models in Chemotherapy Optimization: In a case study involving non-small cell lung cancer (NSCLC) patients, mathematical models were used to simulate different chemotherapy dosing regimens. These models incorporated data on drug pharmacokinetics (how the drug is processed in the body) and pharmacodynamics (the drug's effect on the tumor) to predict the outcomes of various treatment schedules (Smieja, 2023). By adjusting variables such as drug dosage, frequency, and combination therapies, the models identified an optimal regimen that minimized tumor growth while reducing toxicity to healthy tissues.

One of the models employed in this study was based on differential equations that described the interaction between the tumor cells and the chemotherapeutic agents. A simplified version of such a model is:

where T(t) is the tumor cell population, r is the tumor growth rate, K is the carrying capacity (reflecting the maximum tumor size), and C(t) is the concentration of the chemotherapeutic agent. By solving this system of equations, the researchers were able to simulate how different chemotherapy schedules affected the tumor's growth trajectory.

Comparison of Model Predictions with Clinical Outcomes: The predictions made by the mathematical model were compared with clinical outcomes from a group of NSCLC patients undergoing chemotherapy. The optimized regimen suggested by the model not only reduced the tumor size more effectively than standard dosing protocols but also led to fewer side effects, as measured by patient-reported symptoms and blood markers of toxicity (Smieja, 2023).. In some cases, the model even predicted the development of drug resistance before it became clinically apparent, allowing for early adjustments to the treatment plan.

Case Study 3: Modeling Immunotherapy in Melanoma

Immunotherapy has revolutionized the treatment of melanoma, particularly with the advent of immune checkpoint inhibitors that boost the body’s natural immune response to cancer cells. However, predicting which patients will respond to immunotherapy remains a challenge due to the complex interplay between tumor cells, immune cells, and the tumor microenvironment (Nomdedeu-Sancho et al., 2023). Mathematical models have been developed to simulate these interactions and provide insights into the effectiveness of immunotherapy.

Mathematical Models of Immune Responses: One of the most widely studied mathematical models for immunotherapy involves ordinary differential equations (ODEs) that describe the interactions between tumor cells and immune cells, such as cytotoxic T cells and natural killer (NK) cells. These models can simulate how the immune system responds to the introduction of immunotherapeutic agents, such as anti-PD-1 or anti-CTLA-4 antibodies (Unni & Seshaiyer, 2019).

A simple model might look like this:

where T(t) represents the tumor population, I(t) represent the immune cell population, r_T​ and r_I​ are the respective growth rates of tumor and immune cells, K_T ​ is the tumor carrying capacity, and k_I ​ is the rate at which immune cells kill tumor cells. By adjusting parameters such as r_I ​ or k_I ​, the model can simulate how the tumor responds to immunotherapy under different conditions.

Impact on Patient Outcomes: A case study involving melanoma patients treated with immune checkpoint inhibitors demonstrated the predictive power of these mathematical models. In this study, the model was used to simulate patient-specific immune responses to anti-PD-1 therapy. The model’s predictions closely matched the observed clinical outcomes, with patients whose immune responses were predicted to be strong showing significant tumor regression, while those with weaker predicted responses had more limited benefits from the treatment (Butner et al., 2021).

This case study highlights the potential of mathematical models to not only predict patient outcomes but also guide treatment strategies. For instance, patients with a predicted weak immune response might benefit from combination therapies that include both checkpoint inhibitors and other treatments, such as chemotherapy or radiation, to enhance the immune system's ability to fight the tumor.

Challenges and Limitations of Mathematical Modeling in Cancer Research

Integration with Genomics and Personalized Medicine

Conclusions

References

1. Akinbusola, Victoria (2024). Mathematical modeling of neural networks: Bridging the gap between mathematics and neurobiology. World Journal of Advanced Engineering Technology and Sciences, 2024, 13(01), 516–526. [CrossRef]
2. Alinei-Poiana, T., Dulf, Eva-H., & Kovacs, L. (2023). Fractional calculus in mathematical oncology. Scientific Reports, 13(1). [CrossRef]
3. Azizi, T. (2024). Mathematical Modeling of Cancer Progression. AppliedMath, 4(3), 1065–1079. [CrossRef]
4. Bekker, R. A., Kim, S., Pilon-Thomas, S., & Enderling, H. (2022). Mathematical modeling of radiotherapy and its impact on tumor interactions with the immune system. Neoplasia (New York, N.Y.), 28, 100796. [CrossRef]
5. Belkhir, S., Thomas, F., & Roche, B. (2021). Darwinian Approaches for Cancer Treatment: Benefits of Mathematical Modeling. Cancers, 13(17), 4448. [CrossRef]
6. Butner, J. D., Dogra, P., Chung, C., Pasqualini, R., Arap, W., Lowengrub, J., Cristini, V., & Wang, Z. (2022). Mathematical modeling of cancer immunotherapy for personalized clinical translation. Nature computational science, 2(12), 785–796. [CrossRef]
7. Butner, J. D., Wang, Z., Elganainy, D., Al Feghali, K. A., Plodinec, M., Calin, G. A., Dogra, P., Nizzero, S., Ruiz-Ramírez, J., Martin, G. V., Tawbi, H. A., Chung, C., Koay, E. J., Welsh, J. W., Hong, D. S., & Cristini, V. (2021). A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden. Nature Biomedical Engineering, 5(4), 297–308. [CrossRef]
8. Castaneda, M., den Hollander, P., Kuburich, N. A., Rosen, J. M., & Mani, S. A. (2022). Mechanisms of cancer metastasis. Seminars in Cancer Biology, 87(1), 17–31. [CrossRef]
9. Chamseddine, I. M., & Rejniak, K. A. (2019, July 17). Hybrid modeling frameworks of tumor development and treatment. Wiley Online Library; John Wiley & Sons, Inc. [CrossRef]
10. Clare, S. E., Nakhlis, F., & Panetta, J. C. (2000). Molecular biology of breast cancer metastasis. The use of mathematical models to determine relapse and to predict response to chemotherapy in breast cancer. Breast cancer research : BCR, 2(6), 430–435. [CrossRef]
11. de Visser, K. E., & Joyce, J. A. (2023, March 13). The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Doi.org. [CrossRef]
12. Deisboeck, T. S., Wang, Z., Macklin, P., & Cristini, V. (2011). Multiscale cancer modeling. Annual review of biomedical engineering, 13, 127–155. [CrossRef]
13. Duarte, D., & Vale, N. (2022). Evaluation of synergism in drug combinations and reference models for future orientations in oncology. Current Research in Pharmacology and Drug Discovery, 3, 100110. [CrossRef]
14. Enderling, H. (2022). Mathematical oncology: A new frontier in cancer biology and clinical decision making. Physics of Life Reviews, 40, 60–62. [CrossRef]
15. Foo, J., Leder, K., & Michor, F. (2011). Stochastic dynamics of cancer initiation. Physical Biology, 8(1), 015002. [CrossRef]
16. GomezQuiroz, L. E., & Roman, S. (2022). Influence of genetic and environmental risk factors in the development of hepatocellular carcinoma in Mexico. Special Issue on Hepatocellular Carcinoma (HCC) and Hepatitis B and c as Its Main Causes Worldwide, 27, 100649. [CrossRef]
17. Gonçalves, I. G., & GarcíaAznar, J. M. (2023). Hybrid computational models of multicellular tumour growth considering glucose metabolism. Computational and Structural Biotechnology Journal, 21, 1262–1271. [CrossRef]
18. Harshe, I., Enderling, H., & Brady-Nicholls, R. (2023). Predicting Patient-Specific Tumor Dynamics: How Many Measurements Are Necessary?. Cancers, 15(5), 1368. [CrossRef]
19. Hassan, M., Awan, F. M., Naz, A., deAndrés-Galiana, E. J., Alvarez, O., Cernea, A., Fernández-Brillet, L., Fernández-Martínez, J. L., & Kloczkowski, A. (2022). Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. International journal of molecular sciences, 23(9), 4645. [CrossRef]
20. Israel, G. (1988). On the contribution of Volterra and Lotka to the development of modern biomathematics. History and Philosophy of the Life Sciences, 10, 37–49.
21. Johnson, K. E., Howard, G., Mo, W., Strasser, M. K., Lima, E. A. B. F., Huang, S., & Brock, A. (2019). Cancer cell population growth kinetics at low densities deviate from the exponential growth model and suggest an Allee effect. PLoS Biology, 17(8), e3000399. [CrossRef]
22. Li H. (2023). Invalidity of, and alternative to, the linear quadratic model as a predictive model for postirradiation cell survival. Cancer science, 114(7), 2931–2938. [CrossRef]
23. Lunk, B. (2019). PICUP Exercise Sets: A Stochastic Model of Birth-Death Population Dynamics. PICUP. https://www.compadre.org/PICUP/exercises/exercise.cfm?A=BirthDeath.
24. Matin, H. N., & Setayeshi, S. (2024). A computational tumor growth model experience based on molecular dynamics point of view using deep cellular automata. Artificial Intelligence in Medicine, 148, 102752. [CrossRef]
25. McAleer, S. (2022). A history of cancer and its treatment: Presidential Address to the Ulster Medical Society. 7th October 2021. The Ulster Medical Journal, 91(3), 124–129. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720583/.
26. Michor, F., & Beal, K. (2015). Improving Cancer Treatment via Mathematical Modeling: Surmounting the Challenges Is Worth the Effort. Cell, 163(5), 1059–1063. [CrossRef]
27. National Cancer Institute. (2021, October 11). What Is Cancer? - National Cancer Institute. Www.cancer.gov. https://www.cancer.gov/about-cancer/understanding/what-is-cancer#.
28. Nidal Al-Huniti, Yan, F., Jingyu Jerry Yu, Zheng Rong Lü, Nagase, M., Zhou, D., & Sheng, J. (2020). Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities. CPT: Pharmacometrics & Systems Pharmacology, 9(8), 419–427. [CrossRef]
29. Nivlouei J., S., Soltani, M., Shirani, E., Salimpour, M. R., Travasso, R., & Carvalho, J. (2022). A multiscale cell-based model of tumor growth for chemotherapy assessment and tumor-targeted therapy through a 3D computational approach. Cell proliferation, 55(3), e13187. [CrossRef]
30. Nomdedeu-Sancho, G., Gorkun, A., Mahajan, N., Willson, K., Schaaf, C. R., Votanopoulos, K. I., Atala, A., & Soker, S. (2023). In Vitro Three-Dimensional (3D) Models for Melanoma Immunotherapy. Cancers, 15(24), 5779. [CrossRef]
31. Norton, K. A., Gong, C., Jamalian, S., & Popel, A. S. (2019). Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. Processes (Basel, Switzerland), 7(1), 37. [CrossRef]
32. Norton, K.-A., Gong, C., Jamalian, S., & Popel, A. S. (2019). Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. Processes, 7(1), 37. [CrossRef]
33. Odoux, C., Fohrer, H., Hoppo, T., Guzik, L., Stolz, D. B., Lewis, D. W., Gollin, S. M., Gamblin, T. C., Geller, D. A., & Lagasse, E. (2019). A Stochastic Model for Cancer Stem Cell Origin in Metastatic Colon Cancer. Cancer Research, 68(17), 6932–6941. [CrossRef]
34. Olushola, A. , Mart, J. , (2022). Fraud Detection Using Machine Learning Techniques. http://dx.doi.org/10.13140/RG.2.2.33044.88961/1.
35. Olushola, A. , Mart, J. , Alao, V. , (2023). Implementations Of Artificial Intelligence In Health Care. http://dx.doi.org/10.13140/RG.2.2.36344.62729/1.
36. Olushola, A. , Mart, J. , Alao, V. , (2023). Predictive Modelling For Disease Outbreak Prediction. http://dx.doi.org/10.13140/RG.2.2.17470.25929/1.
37. Panja, S., Rahem, S., Chu, C. J., & Mitrofanova, A. (2021). Big Data to Knowledge: Application of Machine Learning to Predictive Modeling of Therapeutic Response in Cancer. Current genomics, 22(4), 244–266. [CrossRef]
38. Petinrin, O. O., Saeed, F., Toseef, M., Liu, Z., Basurra, S., Muyide, I. O., Li, X., Lin, Q., & Wong, K.-C. (2023). Machine learning in metastatic cancer research: Potentials, possibilities, and prospects. Machine Learning in Metastatic Cancer Research: Potentials, Possibilities, and Prospects, 21, 2454–2470. [CrossRef]
39. Poleszczuk, J., Macklin, P., & Enderling, H. (2016). Agent-Based Modeling of Cancer Stem Cell Driven Solid Tumor Growth. Methods in Molecular Biology (Clifton, N.J.), 1516, 335–346. [CrossRef]
40. Smieja J. (2023). Mathematical Modeling Support for Lung Cancer Therapy-A Short Review. International journal of molecular sciences, 24(19), 14516. [CrossRef]
41. Spoormans, K., Crabbé, M., Struelens, L., De Saint-Hubert, M., & Koole, M. (2022). A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT). Pharmaceutics, 14(10), 2007. [CrossRef]
42. Sun, X., & Hu, B. (2018). Mathematical modeling and computational prediction of cancer drug resistance. Briefings in bioinformatics, 19(6), 1382–1399. [CrossRef]
43. Szumilak, M., Wiktorowska-Owczarek, A., & Stanczak, A. (2021). Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance?. Molecules (Basel, Switzerland), 26(9), 2601. [CrossRef]
44. Thirumal, R. A., Patil, S., Sarode, S., Sarode, G., Gadbail, A., & Gondivkar, S. (2018). Scope of Mathematical Biology in Cancer Research. The Journal of Contemporary Dental Practice, 19, 1035–1036. [CrossRef]
45. Unni, P., & Seshaiyer, P. (2019). Mathematical Modeling, Analysis, and Simulation of Tumor Dynamics with Drug Interventions. Computational and mathematical methods in medicine, 2019, 4079298. [CrossRef]
46. Vaia. (2019). Biomathematics: Applications & Implications | Vaia. Vaia. https://www.vaia.com/en-us/explanations/math/applied-mathematics/biomathematics/.
47. Vieira, L. C., Costa, R. S., & Valério, D. (2023). An overview of mathematical modelling in cancer research: Fractional calculus as modelling tool. Fractal and Fractional, 7, 8. [CrossRef]
48. Vieira, L., Costa, R. S., & Duarte Valério. (2023). An Overview of Mathematical Modelling in Cancer Research: Fractional Calculus as Modelling Tool. Fractal and Fractional, 7(8), 595–595. [CrossRef]
49. Wei, H. (2023). Mathematical modeling of tumor growth and treatment: Triple negative breast cancer. Mathematics and Computers in Simulation, 204, 645–659. [CrossRef]
50. West, J., Robertson-Tessi, M., & Anderson, A. R. A. (2023). Agent-based methods facilitate integrative science in cancer. Trends in cell biology, 33(4), 300–311. [CrossRef]
51. WHO. (2022, February 3). Cancer. World Health Organization. https://www.who.int/news-room/fact-sheets/detail/cancer.
52. Yin, A., Moes, D. J. A. R., van Hasselt, J. G. C., Swen, J. J., & Guchelaar, H. (2019). A Review of Mathematical Models for Tumor Dynamics and Treatment Resistance Evolution of Solid Tumors. CPT: Pharmacometrics & Systems Pharmacology, 8(10), 720–737. [CrossRef]